Kazushige Mizoguchi Selected Research

Yi-Gan San

1/2019	Comparison of the Effects of Yokukansan and Yokukansankachimpihange on Glutamate Uptake by Cultured Astrocytes and Glutamate-Induced Excitotoxicity in Cultured PC12 Cells.
12/2018	Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan.
1/2018	Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook.
1/2017	Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects.
1/2017	Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells.
5/2015	Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice.
1/2015	Protective effects of glycycoumarin and procyanidin B1, active components of traditional Japanese medicine yokukansan, on amyloid β oligomer-induced neuronal death.
1/2014	Yokukansan, a kampo medicine, protects PC12 cells from glutamate-induced death by augmenting gene expression of cystine/glutamate antiporter system Xc-.
8/2013	Glycyrrhiza and Uncaria Hook contribute to protective effect of traditional Japanese medicine yokukansan against amyloid β oligomer-induced neuronal death.
8/2013	Brain region-specific reduction in c-Fos expression associated with an anxiolytic effect of yokukansan in rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazushige Mizoguchi Research Topics

Disease

7	Alzheimer Disease (Alzheimer's Disease) 07/2022 - 08/2007
6	Dementia (Dementias) 10/2021 - 05/2015
6	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020 - 08/2013
2	Frailty 06/2022 - 01/2020
2	Anorexia 01/2022 - 10/2021
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 01/2010
1	Multiple Sclerosis 05/2022
1	Disease Progression 05/2022
1	Leukoencephalopathies 02/2021
1	Anhedonia 01/2021
1	Pelizaeus-Merzbacher Disease 10/2020
1	Cognitive Dysfunction 01/2020
1	Anxiety Disorders (Anxiety Disorder) 01/2020
1	Thiamine Deficiency 01/2019
1	Dyskinesias (Dyskinesia) 01/2016
1	Demyelinating Diseases (Demyelinating Disease) 01/2016
1	Hallucinations (Hallucination) 05/2015
1	Pheochromocytoma 01/2014
1	Chronic Renal Insufficiency 02/2010
1	Renal Insufficiency (Renal Failure) 02/2010
1	Liver Diseases (Liver Disease) 01/2010

Drug/Important Bio-Agent (IBA)

11	Yi-Gan SanIBA 01/2019 - 01/2010
4	ninjin'yoeitoIBA 06/2022 - 01/2021
2	Glutamic Acid (Glutamate)FDA Link 01/2019 - 01/2014
2	Pharmaceutical PreparationsIBA 12/2018 - 05/2015
1	RNA (Ribonucleic Acid)IBA 07/2022
1	CytokinesIBA 05/2022
1	Interleukin-6 (Interleukin 6)IBA 05/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2022
1	Dopamine (Intropin)FDA LinkGeneric 10/2021
1	EnzymesIBA 10/2021
1	Mutant Proteins (Protein, Mutant)IBA 02/2021
1	Proteins (Proteins, Gene)FDA Link 02/2021
1	FilaminsIBA 02/2021
1	Sucrose (Saccharose)IBA 01/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 10/2020
1	kamikihi-to (KKT)IBA 01/2020
1	Memantine (Namenda)FDA Link 12/2018
1	Ether (Diethyl Ether)IBA 01/2018
1	Indole AlkaloidsIBA 01/2018
1	geissoschizineIBA 01/2018
1	Plant ExtractsIBA 01/2016
1	Levodopa (L Dopa)FDA LinkGeneric 01/2016
1	BenserazideIBA 01/2016
1	Protein Isoforms (Isoforms)IBA 01/2016
1	Hallucinogens (Psychedelics)IBA 05/2015
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 05/2015
1	Cystine (L-Cystine)IBA 01/2014
1	AntiportersIBA 01/2014
1	CreatinineIBA 02/2010
1	Parathyroid Hormone (Parathormone)IBA 02/2010
1	CalciumIBA 02/2010
1	NitrogenIBA 02/2010
1	collagen type I trimeric cross-linked peptideIBA 02/2010
1	1,25-dihydroxyvitamin DIBA 02/2010
1	MineralsIBA 02/2010
1	Collagen Type I (Type I Collagen)IBA 02/2010
1	Urea (Carbamide)FDA LinkGeneric 02/2010
1	Adenine FDA LinkGeneric 02/2010
1	Amyloid beta-PeptidesIBA 08/2007

Therapy/Procedure

14	Kampo Medicine (Kampo) 01/2022 - 01/2010
1	Oral Administration 01/2016